Engineered Salmonella typhimurium (S.t-ΔpG lux/pT-ClyA ) and attenuated Salmonella typhimurium (SL: Salmonella typhimurium with a defect in the synthesis of guanine 5′-diphosphate-3′-diphosphate) exhibit similar tumor targeting capabilities (Kim et al. in Theranostics 5:1328-1342 Jiang et al. in Mol Ther 18:635-642, 2013) 
Introduction
Colon cancer is one of the most common malignant tumors in the world. With changing lifestyles and increasing lifespans, the incidence of colon cancer is increasing by the year. In 2018, the estimated number of new cases of colon cancer in the United States was 97,220, and the number of deaths was estimated at 50,630 (Siegel et al. 2018) . Bacterial-mediated cancer therapy (BCT) was originally used to treat solid tumors (Nguyen and Min 2017) . A variety of bacteria have been found to be useful in anti-tumor therapy, such as Bifidobacterium (Luo et al. 2016) , Escherichia (Ninomiya et al. 2014) , Clostridium (Luo et al. 2016) , Salmonella (Park et al. 2016; Nguyen and Min 2017) and Listeria (Loessner and Weiss 2004; van Pijkeren et al. 2010 ). Compared to peripheral tumor proliferative tissues, facultative anaerobic bacteria, such as attenuated Salmonella and Escherichia coli, are more likely to colonize hypoxic and necrotic areas by accurately targeting the hypoxic regions of solid tumors (Xie et al. 2018; Frahm 2015; Bolhassani and Zahedifard 2012) . As conventional therapies fail to provide sustainable remission for most cancer patients, the emerging and unique immune therapeutic approach of bacteria-mediated cancer therapy (BCT) is marching towards a feasible solution.
Attenuated S. typhimurium that is defective in ppGpp (ΔppGpp S. typhimurium) synthesis has tumor-targeting ability and significantly suppresses tumor growth (Cao et al. 2016; Yoon et al. 2018; Vola et al. 2018) . Colonization and subsequent proliferation of ΔppGpp S. typhimurium within tumor tissues induces infiltration of immune cells, such as neutrophils, macrophages, and dendritic cells, which then secrete pro-inflammatory cytokines, such as IL-1β, which contribute to anti-cancer efficacy (Yu 2018; Qu et al. 2012; PalssonMcDermott et al. 2015; Kim et al. 2015) . The latest literature reports that ΔppGpp S. typhimurium exerts anti-cancer effects by promoting secretion of IL-1β from macrophages or dendritic cells. However, this method is typified by tumor recurrence after treatment, which is related with decreased IL-1β levels (Kim et al. 2015) . Some studies have shown that low concentrations of IL-1β promote the secretion of IL-17 from CD4+ T cells, inhibiting the body's anti-tumor mechanisms. High concentrations of IL-1β activate CD8+ T cells, which promotes anti-tumor effects (Ghiringhelli et al. 2009; Bruchard et al. 2013) . IL-1β production is closely related to the toll receptor 4 (TLR4) signaling and NOD-like receptor NLRP3 signaling pathways (Jimenez-Dalmaroni et al. 2016; Kim et al. 2015) . Lipopolysaccharide (LPS) (Mariathasan et al. 2004 ) and cytolysin (ClyA) (Wallace et al. 2000) are important ligands for the activation of TLR4 and NLRP3 signaling pathways, respectively. LPS is an endotoxin of gram-negative bacteria (Kahler et al. 2018) . The ligand bacterial toxin of NLRP3 can be activated from formed plasma membrane pores, thereby activating NLRP3. However, the pores formed on the cell membrane are rapidly closed after the external stimulus is cleared, so it is difficult to maintain sustained release of IL-1β (Jia et al. 2018 ). Of note, cytolysin A (ClyA) can act on the mammalian cell membrane to form a persistent pore, resulting in a significant outflow of K + from the cell (Jia et al. 2018) , thereby activating the NLRP3 inflammatory body pathway (Gupta et al. 2014) . In addition, the combination of attenuated Salmonella and ClyA genes through bioengineering technology may offer the possibility sustained, increased release of IL-1β. This may overcome the phenomenon of tumor recurrence caused by downregulation of IL-1β in the tumor microenvironment during the late stage of colon cancer treatment by a single attenuated Salmonella.
Previous studies have successfully transfected the ClyA gene into ΔppGpp S. typhimurium using genetic engineering technology to form an engineered Salmonella: S.t-ΔpG lux/pT-ClyA , which was confirmed to significantly inhibit subcutaneous inoculation of tumors in CT26 colon cancer (Jiang et al. 2013) . To investigate whether StΔpG lux/pT-ClyA inhibits colon cancer growth by promoting increased production of IL-1β, we dynamically evaluated the efficacy of S.t-ΔpG lux/pT-ClyA for colon cancer treatment by MRI and explored the cellular origin of IL-1β in colon cancer treatment. In addition, we assessed the effect of IL-1β on tumors and analyzed the regulatory mechanisms involved using molecular biology techniques.
Materials and methods

Tumor cell line and animal model
The murine CT26 colon adenocarcinoma cell line was obtained from the cell bank of the Chinese Academy of Sciences (Shanghai, People's Republic of China). Cells were grown at 37 °C and 5% CO 2 in Dulbecco's Modified Eagle's Medium (Gibco ® , Life Technologies, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (HyClone Laboratories, Inc., Logan, UT, USA).
Male BALB/c mice (4-5 weeks old) were purchased from the Experimental Animal Center of Central South University and were housed individually at 22 °C to 25 °C under a 12 h light/dark cycle with free access to food and water. To generate in situ colorectal cancer in mice, CT26 cells were injected into the right side of the mouse through a 1 ml syringe to achieve subcutaneous tumor formation. After the tumor body grew to a certain size, subcutaneous tumor-forming mice were euthanized, and the tumor mass was cut into 1-2 mm pieces. The tumor block was then transplanted into the cecum of a normal mouse to establish an orthotopic colon cancer model, as previously described (Rajput et al. 2008) . When tumor volume exceeded 2000 mm 3 , animals were euthanized and excluded from the experiment. All animal experimental procedures used in this study were approved by the Animal Ethics Committee of Central South University and conducted in accordance with the Guideline of the Care and Use of Laboratory Animals in Central South University.
Animal experiments
Tumor-forming mice were treated with PBS, SL, S. (Chen et al. 2015; Jiang et al. 2010 Jiang et al. , 2013 . We injected 5 µg of IL-1β antibody (AF401-NA, R&D Systems) into tumor-bearing mice via the tail vein 1 day before and during treatment (two times a week). The mice were euthanized, and tumors were isolated at the end of the experiment. The tumor size of each group was measured using MRI. Tumor volumes (mm 3 ) were estimated using the formula (L × H×W)/2 where L is the length, W is the width, and H is the height of the tumor in millimeters (Yu et al. 2004 ).
Preparation of engineered S. typhimurium
The primers, plasmids, and bacterial strains (S. typhimurium ΔppGpp/lux) used in this study were kindly provided by Shengnan Jian (Chonnam National University, South Korea). S. typhimurium ΔppGpp/lux-pTet/ ClyA(S.t-ΔpG lux/pT-ClyA ) were constructed as described previously (Jiang et al. 2013; Williams et al. 2010) . We constructed the plasmid pJL43 based on the plasmid pJL39. The antitumor gene (ClyA) was placed under the control of the TetR system in the pJL43 plasmid and was then transformed into the S. typhimurium ΔppGpp/lux strains. All the primers and constructs used in this study are listed in Tables 1 and 2 .
MRI and optical bioluminescence imaging
Magnetic resonance imaging (MRI) was performed using a 3.0 T MRI system (Signa HDxt; GE Healthcare BioSciences Corp., Piscataway, NJ, USA) with a small animal head coil (Shanghai Chenguang Medical Technologies Co. Ltd, Shanghai, People's Republic of China). MRI sequences and parameters were as follows: T2-weighted sequence (echo train length = 4; repetition time = 3000 ms; echo time = 120 ms; number of averages = 1) and T1-weighted sequence (repetition time = 350 ms; echo time = minimum value; number of average = 2) before and after injection of 0.2 mL contrast medium (gadodiamide, Omniscan; Amersham Health, Princeton, NJ, USA). Images were acquired for eight slices in the axial plane (slice thickness = 2.0 mm; matrix = 256 × 192). Mice were anesthetized with isoflurane (initial dose 2.5%, maintenance 1.6%). Bioluminescence imaging was performed with the IVIS 100 system (Caliper Life, Sciences, Hopkinton, MA, USA) (Jiang et al. 2013; Nguyen et al. 2010; Massoud and Gambhir 2003) . ImageJ was used to measure tumor volume and necrotic volume.
Western blot analysis, immunofluorescence and antibodies
The third day after bacterial treatment, tumor tissue was taken. After resecting tumors from rats, tumors were homogenized on ice in RIPA buffer (Sigma-Aldrich Co.) containing protease inhibitor cocktail (Sigma-Aldrich Co.). After 120 min of incubation and 30 min of centrifugation (12,000 rpm at 4 °C), the supernatant was then pipetted off and kept on ice. Protein concentrations were measured using the bicinchoninic acid assay kit (Bio-Rad Laboratories Inc., Hercules, CA, USA). Protein samples were subjected to SDS-PAGE and transferred to a nitrocellulose membrane (Bio-Rad). Membranes were probed with polyclonal goat anti-mouse antibodies followed by horseradish peroxidase-conjugated donkey anti-goat IgG (sc-2020, Santa Cruz Biotechnology; 1:2000 dilution). Protein levels were determined using enhanced chemiluminescence plus (Amersham, Buckinghamshire, UK) and Image Reader (LAS-3000 Imaging System; Fuji Photo Film, Tokyo, Japan). Details concerning protein extraction and western blot (WB) can be found in our previous study (Chen et al. 2015) .
Immunol Fluorescence was performed using the Immunol Fluorescence Staining Kit with kFluor555-labeled goat anti-rabbit IgG (Keygenbiotech) according to the manufacturer's instructions. For immunofluorescence staining, tissue sections were permeabilized and blocked in TBS containing 0.1% Tween 20, 0.3% Triton X-100, and 5% BSA. Sections were then incubated with antibodies overnight at 4 °C followed by addition of secondary antibodies (all from Invitrogen). All antibodies were diluted 1:200 in TBS containing 0.1% Tween 20, 1% BSA, and 0.1% Triton X-100. Samples were mounted using Pro-long ® Gold antifade reagent (P36930, Invitrogen) and analyzed under a Fluoview-1000 (FV-1000) laser scanning confocal microscope (Olympus). The antibodies used in this article are as follows: NLRP3 (1:1000), ASC (1:1000), Caspase-1 (1:500), IL-1β (1:300), TLR4 (1:1000), MyD88 (1;500), NF-κB (1;300), GAPDH (1:500). Antibodies for NLRP3, ASC and caspase-1 were from Adipogen International (San Diego, CA, USA). Antibody for IL-1β, TLR4 and MyD88 was purchased from R&D Systems (Minneapolis, MN, USA). NF-κB were from Cell Signaling Technology (Beverly, MA, USA). Antibody for GAPDH was from SigmaAldrich (St. Louis, MO, USA). Secondary antibodies for western blot were from Sigma-Aldrich (St. Louis, MO, USA). Secondary antibodies for immunofluorescence were from Jackson Immunoresearch Laboratories (West Grove, PA, USA) and Abcam (Cambridge, MA, USA).
Measurement of IL-1β levels in tumor tissues and serum
Blood was collected by cardiac puncture at 0, 0.5, 3, 12 and 24 h, and then serum was harvested by removing the clotted blood after centrifugation. Cytokine levels were measured using individual ELISA kits (eBioscience) according to the manufacturer's instructions. The substrate color reaction was measured at 450 nm in an ELISA plate reader (SpectraMax, Molecular Devices).
Flow cytometry analysis
Mice were euthanized, and spleen tissue was isolated and made into a single cell suspension for flow cytometry analysis. Cells were digested with 0.25% trypsin, centrifuged, and then resuspended in PBS and transferred to an EP tube. Cells were fixed with the addition of 200 µl of 1% paraformaldehyde. Cells were washed with PBS and 200 µl of 90% methanol was added, and cells were then placed at 4 °C. The primary antibody was incubated after washing with PBS. Antibodies used in these experiments include CD11c (N418), CD68 (FA-11), Ly6C (HK1.4), Ly6G (1A8), and IL-1β (NJTEN3). The secondary antibody was incubated after washing with PBS. Flow cytometry was performed using a BD LSR II and BD FACS Aria III flow cytometer (BD Bioscience), and data were analyzed using FlowJo software (TreeStar, Ashland, OR).
Statistical analysis
GraphPad Prism 7 software was used to analyze data. Survival analysis was performed using a Kaplan-Meier curve. All data are expressed as the mean ± SD, and data were considered significant at p < 0.05.
Results
Establishment of BALB/c colon cancer model
58 BALB/c mice were subjected to orthotopic colon cancer surgery with no deaths occurring during the operation. During the recovery period of 4 days, 8 mice died. On the fifth day after surgery, mice were randomly divided into 5 groups: tumor-bearing mice treated with PBS, SL, S.t-ΔpG lux/pT-ClyA (+/−Doxycycline induction) , S.t-ΔpG lux/pTClyA + IL-1βAb. The modeling process is shown in Fig. 1 . Wu et al. AMB Expr (2019) ) is indicated with arrow Fig. 2 Imaging of lux/pT-ClyA-expressing S. typhimurium in a mouse model of cecal colon cancer. BALB/c mice were surgically implanted with CT26 tumors, each measuring 1-2 mm 3 , with fragments being transplanted onto the ceca colon. Distribution of bacteria visualized by in vivo bioluminescence imaging after injection of engineered Salmonella typhimurium secreting lux/pT-ClyA. Images show representative mice before and after euthanasia. a Bioluminescence image shows that bacteria began to colonize the tumor the third day after the injection of the engineered bacteria into the tail vein. b On the sixth day, mice were dissected. L liver, S spleen, K kidney, H heart, L lung (the above images are from the same mouse)
Lux/pT-ClyA-secreting engineered bacteria to target CT26 tumor mice
We examined the tumor-targeting activity of S.t-ΔpG lux/ pT-ClyA in BALB/c mice with CT26 cecal cancer. Bacterial bioluminescence was detected in tumors of injected mice (Fig. 2) . These results indicate that the genetically engineered bacteria maintained their ability to target tumors.
Tumor suppressive effects of engineered bacteria secreting lux/pT-ClyA BALB/c mice transplanted with CT26 tumors were intravenously injected with PBS, ΔppGpp S. typhimurium (SL), or ΔppGpp S. typhimurium carrying ClyA (S.t-ΔpG lux/pT-ClyA ) to evaluate the antitumor activity of engineered bacteria. Previous research reported tumor recurrence after treatment, which was related to decreased IL-1β levels (Kim et al. 2015) . We examined the role of IL-1β in Salmonella-mediated cancer therapy by blocking its activity with an anti-IL-1β antibody. As such, a separate group received an intratumoral injection of ΔppGpp S. typhimurium carrying ClyA + anti-IL-1β antibody (S.t-ΔpG lux/pT-ClyA + IL-1β Ab). We discovered ΔppGpp S. typhimurium carrying lux/pT-ClyA exerted the strongest inhibitory effect on tumor growth induced by doxycycline compared to other groups. In contrast, other groups' tumors regrew at the end of treatment. Tumors injected with PBS grew at the same rate as nontreated tumors. These results indicate that treatment with engineered Salmonella expressing lux/pT-ClyA results in significant suppression of tumor growth, and IL-1β production by S.t-ΔpG lux/pT-ClyA increases therapeutic efficacy (Fig. 3a, b) . In addition, the group of animals that received engineered lux/pT-ClyA-expressing bacteria exhibited higher survival rates than other groups (Fig. 3c) .
Next, tumors were visualized after dissection. The visual map clearly shows that the tumor volume of mice treated with ΔppGpp S. typhimurium carrying ClyA (+Doxycycline induction) group was smaller compared to other groups (Fig. 4) .
Secreting-lux/pT-ClyA engineered Salmonella induce elevated IL-1β serum levels
We examined serum levels of IL-1β in each group. We found that IL-1β serum levels were significantly higher in mice treated with expressing-lux/pT-ClyA S.t-ΔpG lux/pTClyA than in other groups treated with PBS, SL, SL pluxpT-ClyA(−), SLplux-pT-ClyA(+)+IL-1β Ab, respectively (Fig. 5a) . Specifically, we analyzed serum IL-1β levels in PBS, SL, and S.t-ΔpG lux/pT-ClyA(+) groups at indicated times (Fig. 5b) . Result indicated that secreting-lux/ pT-ClyA engineered Salmonella increased production of IL-1β in serum. +IL-1β Ab had many infiltrated immune cells, but IL-1β was rarely produced (Fig. 6a-c) . Flow cytometry analysis supported the IF microscopic findings, showing that treatment with engineered Salmonella led to significant increases in IL-1β expression (Fig. 6d) .
Dendritic cells and macrophages
Engineered Salmonella typhimurium secreting ClyA enhances cancer immunotherapy by secreting IL-1β through two pathways
To determine whether the antitumor effects of lux/pTClyA-secreting ΔppGpp S. typhimurium were mediated through host TLR4 and NLRP3 signaling pathways, we investigated expression levels of NLRP3, ASC, caspase1, TLR4, MyD88, and NF-kB in control and experimental group tumor tissues using western blotting (Fig. 7) .
Results demonstrated that mice treated with S.tΔpG lux/pT-ClyA exhibited significant increases in IL-1β was notably increased, and TLR4 and NLRP3 signaling pathways were markedly activated, with their expression levels being significantly higher than other groups. Thus, in the present study, upregulation of IL-1β was observed, indicating that engineered S. typhimurium secreting lux/ pT-ClyA enhances cancer immunotherapy by inducing IL-1β expression through two pathways.
Discussion
Lipopolysaccharide (LPS) and cytolysin (ClyA) are important ligands for the activation of toll-like receptor 4 (TLR4) and NOD-like receptor (NLRP3) signaling pathways, respectively (Gupta et al. 2014; Wallace et al. 2000; Mariathasan et al. 2004) . IL-1β production is closely correlated with TLR4 and NLRP3 signaling pathways (Phongsisay 2016; Jimenez-Dalmaroni et al. 2016 ).
Moreover, both innate immune cells and colon cancer cells exhibit expression of TLR4 and NLRP3 inflammatory bodies (Basith et al. 2012; Ungerback et al. 2012; Tang et al. 2010; Lee et al. 2012) . Activation of the TLR4 signaling pathway leads to activation of extracellular TLR4 via the MyD88-dependent pathway, forming a TLR4 homodimer. Activated TLR4 binds to the C-terminal TIR of the intracytoplasmic junction protein MyD88 
+IL-1βAb
via the toll/IL-1 receptor homology region (TIR) in the cytoplasmic region and is recruited by the N-terminal death domain of MyD88 to bind to the IL-1 receptor. The kinase (IRAK) activating the TIR-MyD88/IRAK-NFkB pathway expresses the inflammatory cytokine IL-1β (Additional file 1: Figure S1 ) (Shcheblyakov et al. 2010; Mariathasan et al. 2004; Lee et al. 2012) . NLRP3 activation of the N-terminal thermoprotein domain (PYD) causes NLRP3 self-oligomerization, which in turn binds to apoptosis-associated microparticle proteins and recruits Pro-caspase1 to form the NLRP3 inflammatory complex (Strowig et al. 2012) . Upon activation of the inflammatory complex, Pro-caspase 1 is cleaved to form caspase 1, which then promotes IL-1β release to the extracellular environment. We found that K+ efflux is a necessary signal for NLRP3 activation, and Cytolysin A (ClyA) forms a channel on the cell membrane that causes a large and sustained K+ outflow, activating the NLRP3 pathway and promoting sustained IL-1β release (Wallace et al. 2000) (Additional file 2: Figure S2 ). Our previous studies successfully transfected the ClyA gene into attenuated Salmonella ΔppGpp by genetic engineering technology to form engineered Salmonella St-ΔpG lux/ pT-ClyA and confirmed that the construct had an obvious inhibitory effect on subcutaneous tumor inoculation of CT26 colorectal cancer (Jiang et al. 2013) . We hypothesized that engineered Salmonella S.t-ΔpG lux/pT-ClyA acts by activating TLR4 and NLRP3 signaling pathways to promote increased and sustained IL-1β production. In this research, ELISA results showed that colonization of the engineered Salmonella S.t-ΔpG lux/pT-ClyA resulted in a significant increase in serum IL-1β levels compared -treated tumors, expression of involved signaling pathway molecules, such as NLRP3, ASC, Caspase1, TLR4, MyD88, NF-kB and IL-1β, were up regulated; however, TLR4, MyD88, NF-kB and IL-1β were up regulated and NLRP3, ASC, and Caspase1 were rarely expressed or not expressed in the ΔppGpp S. typhimurium group. These findings confirmed our hypothesis that engineered Salmonella S.t-ΔpG lux/pTClyA significantly activates TLR4 and NLRP3 signaling pathways, which promotes sustained IL-1β production through two pathways. Phan et al. showed showed highly expression of NLRP3 when treated with this bacterial strain only , which is different from our results and we will be further demonstrated in the next experiment.
This study demonstrated that IL-1β plays an important role in the anti-tumor process, and IL-1β source cells were primarily monocytes (Hazuda et al. 1990 ), macrophages (Netea et al. 2009 ), dendritic cells (Ghiringhelli et al. 2009 ) and neutrophils (Guma et al. 2009 ). Dendritic cell-derived IL-1β exerts anti-tumor effects by promoting CD8+ T cells to produce IFN-γ (Ghiringhelli et al. 2009 ). Recent studies confirmed that tumor cell-derived IL-1β increases the survival rate of EB virus-induced nasopharyngeal carcinoma via recruiting concentrated granulocytes (Chen et al. 2012) . However, other studies found that low IL-1β concentrations promote CD4+ T cells to secrete IL-17, inhibiting the body's anti-tumor effects, while high IL-1β concentrations activate CD8 + T cells and promote anti-tumor effects (Ghiringhelli et al. 2009; Bruchard et al. 2013 ). This suggests that the IL-1β antitumor activity is concentration-dependent, and increasing IL-1β concentration will increase its anti-tumor effects. The ΔppGpp S. typhimurium lipopolysaccharide (LPS) promoted mononuclear/macrophage and dendritic cells to secrete IL-1β through the TLR4 signaling pathway, exerting anti-cancer effects, but tumor recurrence occurred in late treatment stages, which might be related to reduced IL-1β levels (Kim et al. 2015) . Results of this research show that blocking IL-1β activity using an IL-1β antibody abolished the anti-tumor effects of 
S.t-ΔpG
lux/pT-ClyA . Given these results, IL-1β has potential anti-cancer activity in the context of bacterial-mediated tumor immunotherapy. Treatment with ΔppGpp S. typhimurium alone resulted in transient tumor suppression. Then, tumors began to grow again, and IL-1β levels returned to baseline. However, treatment with engineered Salmonella S.t-ΔpG lux/pT-ClyA consistently inhibited tumor growth, and IL-1β levels remained high. The survival rate of mice treated with engineered Salmonella S.t-ΔpG lux/pT-ClyA was significantly higher than other experimental groups, indicating that the attenuated Salmonella LPS and ClyA genes were combined by bioengineering technology to release high levels of IL-1β, inhibit tumor growth and improve survival rate. This overcame the tumor recurrence phenomenon caused by downregulation of IL-1β during late stages of colon cancer treated with ΔppGpp S. typhimurium alone.
Immunofluorescence results demonstrated that treatment of tumors with S.t-ΔpG lux/pT-ClyA resulted in a significant increase in tumor infiltration by macrophages (CD68), dendritic cells (CD11c), and neutrophils (Ly-6G/Ly-6C). Previous studies revealed that colonization and proliferation of engineered bacteria significantly increased the proportion of M1-like macrophages and reduced the number of Tregs in tumor tissues (Kim et al. 2015) . This means that the engineered bacteria inhibited tumor growth by enhancing the anti-tumor immune response rather than by directly inhibiting growth of the tumor itself. Herein, we found that infiltrating tumor cells produced significant levels of IL-1β in response to intravenous injection of engineered bacteria, resulting in inhibition of tumor growth. In addition, we found that immune cells, particularly dendritic cells and macrophages, were the primary sources of IL-1β production in colonized tumors. In conclusion, S.t-ΔpG lux/pT-ClyA showed significant anti-cancer effects in a mouse orthotopic colon cancer model, providing new avenues for colon cancer treatment. LPS and ClyA are important factors in activating TLR4 and NLRP3 signaling pathways, respectively. StΔpG lux/pT-ClyA activated TLR4-MyD88-NF-Kb-IL-1β and NLRP3-ASC-Caspase-1-IL-1β signaling pathways simultaneously, which enhanced tumor suppressive effects and inducing increased IL-1β release; these results act to overcome the tumor recurrence caused by IL-1β downregulation during late stages of colorectal cancer treatment that are a result of treatment with only ΔppGpp S. typhimurium.
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